Skip to main content Skip to secondary navigation

Docket #: S18-278

Hypoxia-mediated resistance of Homologous recombination-deficient cancer cells to PARP inhibitors

Stanford researcher's invivo studies find that combining PARP inhibitors with a hypoxia activated prodrug delays tumor growth.

We are asking parties interested in commercializing this technology to please contact Stanford OTL by Friday, March 29, 2019.

Applications

  • Combining PARP inhibitors with Hypoxia-targeting drugs in HR deficient cancer cells

Advantages

  • Combining PARP inhibitors with Tirapazamine (hypoxia-activated drug) shows significantly higher tumor killing effects when compared to each monotherapy.

Patents

Similar Technologies

Explore similar technologies by keyword: